Press Releases / May 14, 2024
NovaResp Technologies Inc. Raises $3.0M Seed Extension To Support Clinical Testing of its cMAP™ Positive Airway Pressure Software
The most comfortable experience for sleep apnea patients — powered by revolutionary AI
Learn more about cMAP™Adherence equals traction in the CPAP market
It is estimated that 1 billion people are affected by Obstructive Sleep Apnea (OSA) with 80% undiagnosed. Continuous Positive Airway Pressure (CPAP) therapy is the current gold standard for treating OSA, but adherence to treatment is lower than 50% after the first 3 months of use. By improving adherence to CPAP therapy:
- PATIENTS can have higher quality of life
- MANUFACTURER increased sales of devices and consumables
- DMEs reduce labor costs and improve rate of device and consumables reimbursement
Improved adherence is the #1 driver for device innovation.
Improving adherence through AI-empowered comfort
cMAP™ is a platform software that uses artificial intelligence and machine learning during PAP therapy to predict and prevent episodes of apnea before they occur. As a result, personalized therapy can be delivered via PAP machines at lower, more comfortable air pressure levels.
Learn more about CMAP™
cMAP™ has been designed for compatibility with all major PAP machines
Learn about the benefits that increased adherence can have for your company.
Contact Us
About Obstructive Sleep Apnea (OSA)
OSA is a sleep-related breathing disorder, affecting millions of people worldwide. Obstructive Sleep apnea is characterized by pauses in breathing or periods of shallow breathing during sleep. OSA is caused by complete (apnea) or partial (hypopnea) obstruction of the upper airway.
Want to learn more?
Learn about the benefits that increased adherence can have for your company
Contact Us
